Expression and/or activity of eNOS substantially decreases in response to classic atherogenic culprits such as chronic inflammation (TNF, interleukin 1, and IFNγ), oxidative stress, hypoxia, hyperglycemia, and dyslipidemias (45–48). Here, IFNG is linked to Hyperglycemia.